Spero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for patients with serious infections, particularly those caused by multidrug-resistant bacteria
The company leverages its proprietary technologies and scientific expertise to create new antibiotic therapies aimed at addressing unmet medical needs in the field of infectious diseases. Spero's research and development efforts center on both antibiotic candidates and novel formulations to improve patient outcomes and expand treatment options for healthcare providers. Through its commitment to advancing antibacterial therapies, Spero aims to combat the growing challenge of antibiotic resistance and enhance the quality of care for affected patients.
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on behalf of long-term stockholders following a class action complaint that was filed against Spero with a Class Period from October 28, 2021 to May 2, 2022. Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
